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1 Introduction 
Development of cancer requires genetic events such as chromosomal translocations and 
deletions as well as point mutations that affect cell growth, survival and proliferation. In 
some types of cancer, genetic alterations are believed to be insufficient to induce malignant 
transformation and epigenetic changes are invoked to play a key role in the establishment of 
the full malignant phenotype. More recently, microRNA (miRNA) deregulation has been 
shown to be involved in the development of most, if not all, cancer subtypes (Croce, 2009). 
MiRNAs play a pivotal role in regulation of key processes such as development, 
differentiation and apoptosis. MiRNAs are 19 to 22 nucleotides long and highly conserved 
across species. MiRNA genes represent approximately 1% of the genome and are commonly 
transcribed by RNA polymerase II in a long pri-miRNA which is then processed in the nucleus 
by the Drosha/DGCR8 multiprotein complex to form a 70-100nt long pre-miRNA. Pre-miRNA 
is exported from the nucleus to the cytoplasm by Exportin-5 where an additional processing 
step mediated by Dicer generates a miRNA duplex of approximately 22nt. The MiRNA duplex 
is separated and the guide strand loaded onto the RNA-induced silencing complex (RISC) 
whereas the carrier strand is degraded. In the RISC mature miRNAs are able to regulate gene 
expression at the post-transcriptional level by binding the 3’ untranslated region (UTR) of 
messengerRNA (mRNA) leading to mRNA degradation or inhibition of translation, depending 
on the level of complementarity (figure 1).  A single miRNA can target different mRNAs and it 
is believed that approximately 30% of the genes are subject to post-transcriptional control 
by miRNAs (Iorio, 2009). Generally, members of the same miRNA family have identical 
targets because they share a common seed sequence of 7 or 8 nucleotides which interacts 
with mRNA (Bartel, 2009).  
Expression of miRNAs can be altered by several mechanisms. MiRNA loci deletions, 
amplifications or mutations have been described in various malignancies (Calin, 2002) 
(Raveche, 2007). In addition, recent publications describe broad miRNA repression or block 
of maturation in cancer that may contribute to enhance tumorigenesis (Kumar, 2007). Genes 
encoding proteins involved in the maturation and processing of miRNAs can also be mutated 
or down-regulated. Indeed, Exportin-5 which transports pre-miRNA from the nucleus to the 
cytoplasm and the RISC-subunit TARBP2 can both be mutated (Melo, 2009 and 2010). More  
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Figure 1 : MicroRNA biogenesis and post-transcriptional regulation.  
 Chen, NEJM, 2005 
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recently, it has been shown that several types of cancer can be treated by exogenous 
administration of specific miRNAs in mouse xenotransplant models (Garzon, 2010). Taken 
together, these observations indicate that miRNAs are strongly implicated in tumorigenesis 
and that they are a potentially valuable target for therapeutic intervention.  
Recent work from our laboratory has identified several miRNAs that play a role in Ewing’s 
sarcoma and shown that repression of miRNA-145 is implicated in the emergence of cancer 
stem cells (CSC) and that let-7a down-regulation contributes to Ewing’s sarcoma 
pathogenesis (Riggi, 2010) (De Vito, 2011). Ewing’s sarcoma family tumors (ESFT) are the 
second most common bone malignancy in young adults and children. ESFT are characterized 
by unique chromosomal translocations that in 85% of cases lead to the expression of the 
EWS-FLI1 fusion protein t(11;22). EWS-FLI1 acts as an aberrant transcription factor that can 
both induce and repress target genes. Interestingly, expression of EWS-FLI1 in human 
mesenchymal stem cells (MSCs), the most likely cell of origin of Ewing’s sarcoma, reproduces 
the ESFT phenotype (Riggi, 2010). 
To identify miRNAs that may play a role in ESFT pathogenesis our laboratory performed 
miRNA profiling of MSCs and different ESFT cell lines. The expression profile revealed a 
repression of the entire let-7 family (figure 2), miRNA-100, miRNA-125b and miRNA-31. 
Interestingly, miRNA-100, miRNA 125b and miRNA let-7a belong to the same intergenic 
cluster and are transcribed as a single pri-miRNA in Drosophila. In contrast, the oncogenic 
miRNA 17-92 cluster, miRNA-106a and miRNA-106b are induced in ESFT (De Vito, 2011). The 
let-7 family is of particular interest because it is often deregulated in various malignancies 
and has been shown to contribute to the emergence of CSC in breast cancer (Yu, 2007). Low 
levels of let-7 are associated with poor prognosis and tumor aggressiveness (Büssing, 2008). 
Let-7 is implicated in the post-transcriptional regulation of several oncogenes including c-
MYC, k-RAS or HMGA2 (Roush, 2008). 
Let-7 family members are regulated by Lin28 and its isoform Lin28B which block their 
maturation by binding to their terminal loop and preventing their processing by 
Drosha/DGCR8. Moreover, Lin28/Lin28B are able to recruit a TUTase that uridylates pre-let-7 
leading to its degradation (Heo, 2008), (Viswanathan, 2010), (figure 3). Lin28 is a highly 
conserved RNA binding protein that was first identified in C. elegans where it plays a pivotal  
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Figure 2  
Figure 2 : Relative expression level of let-7 in primary ESFT and different ESFT cell lines reveals a global reduction of all the let-7. 
De Vito et al., Plos One, 2011 ; Figure 3 : In pluripotent or transformed cells Lin28 is induced and affects the let-7 processing. Lin28 
is able to bind the pri-let-7 loop, preventing the processing by DGCR8/Pasha. Furthermore, in the presence of Lin28, the pre-let-7 
is uridylated by TUT4 and degraded. In differentiated cells, the Lin28 locus is epigenetically not accessible and the let-7 precursors 
are processed into mature let-7 miRNAs. As a result, main oncogenes are post-transcriptionally down-regulated (Ras, Myc, 
HMGA2,…) and the pluripotent state is maintained (e.g Blimp-1). Viswanathan, Cell, 2010. 
Figure 3 
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role in developmental timing. Repression of the let-7 family by Lin28 or Lin28B is important 
in establishing the pluripotent state. Indeed, Lin28 together with OCT4, SOX2 and NANOG is 
able to reprogram fibroblasts toward induced pluripotent stem cells (Okita, 2008). Lin28 and 
Lin28B are expressed in many different tumors with a frequency of 15% and are strongly 
induced in those that are poorly differentiated and aggressive (Viswanathan,2009). We 
previously observed that Lin28B, but not Lin28, is overexpressed in primary ESFT and ESFT 
cell lines compared to MSCs (De Vito, 2011). Lin28B also displays let-7 independent 
functions, including impairment of processing of other miRNAs or stabilizing the mRNA of 
the cancer stem cell markers CD133 and LGR5 (Wang, 2010). 
The aim of this work was to determine whether broad let-7 family repression can be 
reproduced in MSCs, the candidate cell of origin of ESFT, by stable expression of Lin28B. 
EWS-FLI1 itself is also able to modulate the expression level of several miRNAs, including let-
7a and miRNA-145. Consequently, we also evaluated the let-7 expression profile of MSCs co-
expressing Lin28B and EWS-FLI1. In addition, we determined which let-7 regulated 
oncogenes are affected by enforced expression of Lin28B. Finally, we evaluated the 
tumorigenic potential of MSCs expressing EWS-FLI1 and Lin28B. 
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2 Results 
2.1 Expression of EWS-FLI1 & Lin28B in human pediatric mesenchymal stem cells (hpMSCs) 
To assess the effect of Lin28B and EWS-FLI1 on let-7 and other miRNAs two vectors 
containing these genes were constructed.  
MSCs are highly sensitive to in vitro manipulation and rapidly undergo apoptosis if infected 
repeatedly. A vector containing an internal ribosomal entry site (IRES) was therefore used 
because it permits the expression of two genes with a single retroviral infection.  
To obtain Lin28B cDNA, RT-PCR from total RNA of primary ESFT was performed. Specific 
primers were designed that correspond to isoform 1 of Lin28B with the desired restriction 
sites. (Isoform 2 has no RNA interacting domain). Lin28B cDNA was amplified by polymerase 
chain reaction (PCR) and the presence and size of the PCR product were verified on an 
agarose gel (figure 4a). DNA was extracted using a column kit and was subsequently digested 
with MluI and PmeI restriction enzymes. The pIRES vector was digested using the same 
restriction enzymes and the insert was ligated to the adjusted vector. The ligated DNA was 
precipitated and electroporated into bacteria that we selected for ampicillin resistance.  
Colonies were picked and screened for the presence of Lin28B by PCR, using one primer 
designed to anneal on the backbone and another to the insert. Thirteen positive colonies 
were obtained (figure 4b) and two were grown overnight. A mini-prep was performed to 
recover the DNA and the vector was sequenced to confirm the presence of Lin28B and to 
exclude mutations. The same steps were then repeated with EWS-FLI1 in order to insert it at 
the 5’ end of the IRES gene. Finally, a colony containing both EWS-FLI1 and Lin28B on the 
pIRES vector was grown. Preparative amounts of DNA were recovered for retroviral 
infection. Lin28B was also inserted into a pMSCV vector.  
GP2 cells were transfected with a packaging vector and the pMSCVLin28B or pIRESEWS-FLI1+Lin28B 
vectors. The supernatant containing the viruses was recovered after 72 hours. Two different 
batches of MSCs were infected with the viruses containing the empty pIRES vector, 
pMSCVLin28B or pIRESEWS-FLI1 + Lin28B. Cells were recovered after selection for puromycin 
resistance and culture in knock out (KO) medium, according to the reprogramming protocol. 
KO medium is composed of 20% KO Serum Replacement, 10ng/mL PDGF-BB, 1% penicillin- 
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Figure 4a  Figure 4b  
Figure 4c  
Figure 4a : PCR of Lin28B from primary ESFT cDNA of CD133+ and CD133- fractions. The bands are cut on the picture (arrow). The 
primers used contain the MluI and PmeI restriction sites. We observe many aspecific bands. Figure 4b : Combs 41 to 60 : PCR 
screening of Lin28B in the pIRES vector. The forward primer anneals on the vector, the reverse on Lin28B. Figure 4c : Relative 
expression level tested by qPCR of EWS-FLI1 and Lin28B in mesenchymal stem cells transfected with either empty vector, Lin28B or 
EWS-FLI1 and Lin28B. This experiment confirms the integrity of my vectors at the transcriptional level. Figure 4d : Western blot of 
EWS-FLI1 and Lin28 in order to check the integrity of our vectors at the post-transcriptional level. Lin28B is less expressed in the IRES 
vector, consistent with the results of the qPCR. PA1 is a cell line who highly expresses Lin28B and is commonly used as a positive 
antibody control for Lin28B.  
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streptomycin, and 10ng/mL human recombinant leukemia inhibitory factor (LIF) and 
increases the reprograming potential of MSCs expressing EWS-FLI1 (See material and 
methods and Riggi 2010).  Expression of Lin28B and EWS-FLI1 was verified by qPCR and 
western blot analysis (figures 4c and 4d).  Total RNA and proteins were extracted and used 
for subsequent experiments.  
 
2.2 Lin28B impairs expression of let-7 and miRNA-143 in MSCs 
The expression level of the different let-7 miRNAs was assessed by qPCR using specific 
primers. We observed that MSCLin28B and MSCEWS-FLI1+Lin28B display a two fold reduction of 
mature let-7 expression compared to MSCempty-vector (figure 5). Interestingly, this expression 
profile is similar to the one observed in primary ESFT and ESFT cell lines. Globally, the let-7 
expression level is slightly lower in MSCLin28B than in MSCEWS-FLI1+Lin28B probably due to the 
higher expression levels of Lin28B in the former.  
Members of our laboratory recently showed that EWS-FLI1 itself binds the promoter of let-
7a thereby repressing its expression (De Vito, 2011). In addition, when EWS-FLI1 is expressed 
in MSCs the expression of let-7a is significantly reduced whereas the expression of the other 
miRNAs of the let-7 family remains unaffected (data not shown).  
We observe that the expression level of let-7a is significantly lower in MSC expressing both 
Lin28B and EWS-FLI1. This suggests that in ESFT let-7a is subject to a double repressive 
regulatory mechanism at the transcriptional as well as the post-transcriptional level, as a 
result of direct binding of EWS-FLI-1 to its promoter and Lin28B mediated maturation 
blockade, respectively.  
It has been reported that Lin28B also displays let-7 independent functions, such as 
impairment of the expression of miRNA-107, miRNA-143 and miRNA-200c (Heo, 2009). Our 
laboratory recently uncovered the importance of mir-143 in Ewing’s Sarcoma cancer stem 
cell maintenance and observed that exogenous administration of mir-143 inhibits ESFT 
growth in vivo (Unpublished data). Consequently, we assessed the miRNA-143 expression 
level in MSCLin28B and MSCEWS-FLI1 + Lin28B. We observed, respectively, a 1.59 and 2.2 fold 
reduction of the miRNA-143 expression level compared to MSCempty-vector (figure 5).   
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Taken together, these results suggest that the overexpression of Lin28B might contribute to 
ESFT pathogenesis by downregulating two miRNAs that play a role in this malignancy, 
namely miRNA-let-7a and miRNA-143.  
 
2.3 The let-7 targets IMP-1 and HMGA2 are released in MSCLin28B and MSCEWS-FLI1-Lin28B 
To evaluate whether Lin28B was able to modulate the expression of let-7 oncogenic targets, 
qPCR of k-RAS, HMGA2 and IMP-1 was performed on the RNA of hpMSCLin28B and hpMSCEWS-
FLI1 + Lin28B.  We observed that HMGA2 and IMP-1 were induced in hpMSCLin28B and hpMSCEWS-
FLI1 + Lin28B whereas the expression level of k-RAS remained stable (figure 6a). These 
observations were confirmed by western blot analysis (figure 6b). HMGA2 is a DNA binding 
protein that may act as a transcriptional regulator. Interestingly, HMGA2 expression has 
been associated with mesenchymal tumors, including lipomas, leiomyomas and 
liposarcomas (Henrikson, 2010). 
Recent work from our laboratory has shown that EWS-FLI1 directly targets the let-7a 
promoter thereby releasing the HMGA2 oncogene, which affects tumor growth of ESFT in 
vivo. Indeed, overexpression of let-7a and repression of HMGA2 both block ESFT cell 
tumorigenecity. Exogenous administration of let-7a decreased HMGA2 expression levels and 
reduced ESFT growth in vivo. MSCs expressing both EWS-FLI1 and Lin28B display a higher 
expression level of HMGA2 than the MSCs expressing only Lin28B, respectively 3.32 and 1.56 
fold relative to MSCempty-vector (Figure 6a). This could be explained by the lower let-7a 
expression levels observed in MSCEWS-FLI1 + Lin28B that reflect the cumulative effect of Lin28B 
mediated let-7a repression and direct inhibition of the let-7a promoter by EWS-FLI1.  
IMP-1, also known as insulin growth factor 2 binding protein 1 (IGF2BP1) displayed a 2.2 fold 
induction in hpMSCLin28B and a 2.5 fold induction in hpMSCEWS-FLI1 + Lin28B. The specific role that 
IMP-1 might play in ESFT remains elusive, and not much is known about its role in the 
pathogenesis of cancer. Hence, very recent data uncovered that low let-7 levels observed in 
ovarian cancer upregulate IMP-1 which in turn contributes to enhance resistance to 
chemotherapy with taxanes (Boyerinas, 2011). 
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The expression level of K-RAS remained stable in hpMSCLin28B and hpMSCEWS-FLI1+Lin28B 
compared to hpMSCempty vector. The constitutive expression level of k-RAS is low in MSCs and 
let-7 down-regulation seems insufficient to augment it. Interestingly, in previous 
experiments we observed that enforced expression of let-7a in ESFT cell lines affected 
significantly the expression level of HMGA2, IMP-1 and Lin28B but not k-RAS (Unpublished 
data).  
In summary, our results suggest that expressing both EWS-FLI1 and Lin28B in hpMSCs is able 
to significantly upregulate the let-7 targets HMGA2 and IMP-1 whereas the expression of k-
RAS remains unaffected.   
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Figure 5 : expression level of the let-7 family in MSCempty-vector MSCLin28B and MSCEWS-FLI1+Lin28B ; Figure 6a : 
Relative expression levels of the let-7 target genes HMGA2, IMP-1 and k-RAS in MSCempty-vector MSCLin28B 
MSCEWS-FLI1+Lin28B ; Figure 6b : Western blot analysis of HMGA2 and IMP-1 in MSCempty-vector MSCLin28B and 
MSCEWS-FLI1+Lin28B 
Figure 6a 
Figure 6b 
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2.4 Soft agar colony formation assay of MSCEWS-FLI1+Lin28B 
To determine whether MSCs co-expressing EWS-FLI1 and Lin28B had tumorigenic potential 
we performed a soft agar colony formation assay. Growth in agar is a convenient method to 
evaluate to ability of cell anchorage independent growth, which is a characteristic of 
transformed cells. It has been demonstrated that impaired miRNA processing enhances 
cellular transformation. Low let-7 levels increase the soft agar colony formation capacity and 
transformation of cells in vivo. Indeed, NIH/3T3 cells overexpressing Lin28B formed colonies in 
soft agar and tumors after injection in nude mice (Kumar, 2007). In previous experiments we 
observed that MSCEWS-FLI1 do not grow in soft agar despite their strong genetic and phenotypic 
resemblance to primary ESFT cells (Riggi, 2010).  
MSCEWS-FLI1+Lin28B, MSCLin28B and the A673 Ewing’s sarcoma cell line were plated on agar for 6 weeks. 
A673 were used as positive control (Figure 7a). We observed no significant growth in of MSCEWS-
FLI1+Lin28B (figure 7c) whereas MSCLin28B displayed strong proliferation in agar (figure 7b). This 
experiment confirms the strong transforming capacities of Lin28B as observed in NIH/3T3 cells. 
Among the hypothesis that we considered to explain the absence of growth of MSCEWS-FLI1+Lin28B in 
agar we retained the much lower expression of Lin28B compared to MSCLin28B because of the relative 
inefficiency of the IRES system. Furthermore, we suspect that we used the wrong antibody for 
selection. We will perform the experiments again with other vectors that allow high expression levels 
of both genes. In further experiments we will determine whether we can transform MSCs 
toward Ewing’s sarcoma cells by modulating other members of the miRNA processing 
machinery. 
 
Figure 7a                                                Figure 7b                                              Figure 7c 
Figure 7a : Soft agar colony formation assay of A673 Ewing’s sarcoma cell lines. ; Figure 7b : Soft agar colony formation assay of 
MSC
Lin28b
. ; Figure 7c : Soft agar colony formation assay of MSC
EWS-FLI1 + Lin28B 
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3 Discussion, conclusion and perspectives 
3.1 Lin28B impairs the expression of mature let-7 and miRNA-143 
Enforced expression of Lin28B and EWS-FLI1 in the cell of origin of ESFT reproduces the let-7 
expression profile observed in primary ESFT and in ESFT cell lines. Interestingly, the let-7 
family is regulated by multiple oncogenes, all leading to let-7 down regulation. As discussed 
above, let-7a seems to be repressed in at least two ways in ESFT: by Lin28B blockade of 
maturation and by direct repression of the let-7a promoter by EWS-FLI1. C-MYC which is 
induced by EWS-FLI1 itself in ESFT has been reported to transcriptionally repress let7-a 
(Dauphinot, 2001). In addition, it has been shown that c-MYC can induce Lin28B (Chang, 
2009).  Hence, Lin28B is not induced in MSCEWS-FLI1 and the mechanisms leading to its 
expression in ESFT are not understood yet. Direct repression of let-7a by EWS-FLI1 which in 
turn upregulates Lin28B seems insufficient to induce its expression in MSCEWS-FLI1. MiRNA-
125b, a reported Lin28B target, is strongly repressed in ESFT (McKinsey, 2011). MiRNA-125b 
belongs to the same cluster as let-7a and it is tempting to speculate that its promoter could 
be directly repressed by EWS-FLI1 itself. It would be interesting to determine whether EWS-
FLI1 binds the mir-125b promoter and how it affects the expression level of Lin28B. To 
better understand the meaning of Lin28B mediated let-7 repression we could silence the 
expression of the Lin28B gene in ESFT cell lines using a specific small hairpin RNA (shRNA) 
and assess how it affects tumor growth, proliferation and differentiation.  
It has been reported that Lin28B can also affect the processing of pre-miRNA-107, pre-
miRNA-143, and pre-miRNA-200c by recruiting TUT4 which leads to urydilation of the 
precursor preventing its processing by Dicer (Heo, 2009). Of particular interest is miRNA-143 
because our laboratory recently uncovered its central role in ESFT CSC maintenance and 
showed that exogenous administration of miRNA-143 significantly reduces ESFT tumor 
growth in vivo (Unpublished data). It would be interesting to compare the expression level of 
Lin28B and miRNA-143 in the CD133+ and CD133- fraction of primary ESFT to elucidate more 
fully the role that Lin28B might play in ESFT CSC maintenance or emergence.  
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3.2 Let-7 repression leads to upregulation of the HMGA2 and IGF2BP1 oncogenes 
To understand the significance of Lin28B mediated let-7 repression we analyzed the 
expression level of let-7 regulated oncogenes, namely HMGA2, IGF2BP1 and k-RAS. HMGA2 
is of particular interest because of its association with benign and malignant mesenchymal 
tumors and its implication in ESFT growth (De Vito, 2011). It could be of interest to further 
study the role of HMGA2 in the promotion of stemness and CSC maintenance. Indeed, 
recent data revealed that HMGA2 regulates neural stem cell self-renewal by controlling the 
INK4a locus (Nishino, 2008). Our observations suggest that the cumulative repression of let-
7a by Lin28B and EWS-FLI1 in turn leads to a robust induction of HMGA2 in MSCEWS-FLI1 + Lin28B. 
Furthermore, because of the predicted EWS-FLI1 binding sites in the HMGA2 promoter we 
could determine whether EWS-FLI1 is able to induce HMGA2 directly.  
IMP-1 also seems to be affected by Lin28B-mediated let-7 repression in MSCLin28B and 
MSCEWS-FLI1+Lin28B. The specific role that IMP-1 might play in ESFT pathogenesis has not been 
studied. However, in ovarian cancer, low let-7 and high IMP-1 levels are frequently observed 
and associated with poor prognosis (Köbel, 2007). Ovarian cancers are frequently treated 
with chemotherapy regimens that combine carboplatin and taxanes. Unfortunately, 
resistance to taxanes is often observed. Recent work showed that low let-7 levels observed 
in ovarian cancer upregulate IMP-1 which stabilizes the Multi-Drug-Resistance-1 protein and 
in turn contributes to taxane treatment resistance (Boyerinas 2011). Another known 
function of IMP-1 is to directly bind and stabilize c-MYC mRNA leading to an increase in c-
MYC protein abundance (Köbel, 2007). IMP-1 is expressed only in a small subset of tissues, 
predominantly of fetal origin. Interestingly a study has shown that 73% of malignant 
mesenchymal tumors express IMP-1 and that 14 out of 14 Ewing’s Sarcomas tested were 
positive for IMP-1 (Ioannidis, 2001). This suggests that IMP-1 may play a role in 
mesenchymal tumor pathogenesis and it would be interesting to investigate its putative 
function in that of ESFT. IMP-1 can bind and stabilize the mRNA of IGF-II (Weidensdorfer, 
2009). The IGF signaling pathway is strongly implicated in ESFT growth and survival, but the 
role of IGF-II in ESFT is uncertain and several ESFT cell lines do not express IGF-II. 
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3.3 Lin28B : miRNA regulation, pluripotency and CSC generation ? 
Our laboratory previously showed that hpMSCEWS-FLI1 display a transcriptome that is highly 
similar to that of ESFT and uncovered the mechanisms by which EWS-FLI1 initiates MSC 
reprogramming toward Ewing sarcoma cancer stem cells. EWS-FLI1 is able to modulate the 
expression of several embryonic stem cell genes, in part through repression of mir-145. 
Human pediatric MSCEWS-FLI1 grown under serum-free conditions display a strong induction of 
SOX2, OCT4 and NANOG which are implicated in ESC maintenance and reprogramming. 
Strikingly, the expression of EWS-FLI1 in hpMSC is able to generate a subpopulation of 
CD133+ cells, which has been shown to resemble Ewing Sarcoma CSC. The CD133+ fraction 
of hpMSCEWS-FLI1 has sphere forming ability in vitro but no tumorigenic properties in vivo 
(Suva, 2009) (Riggi, 2010). 
Let-7 family microRNAs are strongly repressed in ESFT and let-7 inhibition by Lin28/Lin28B 
has been associated with malignant transformation in various types of cancer. Moreover, 
Lin28 plays a role in cancer stem cell maintenance and can stabilize the mRNA of the stem 
cell markers CD133/Prominin1 and LGR5 through let-7 independent mechanisms in colon 
cancer (Yang, 2010) (King, 2011). The mechanism by which Lin28B is overexpressed in ESFT is 
unclear and EWS-FLI1 seems unable to induce its expression in hpMSC. Based on our 
observations which suggest that Lin28B might globally reduce mature let-7 expression and in 
turn upregulate oncogenes, we stably co-expressed EWS-FLI1 and Lin28B in hpMSC. The aim 
was to assess, by soft agar colony formation assay, whether upregulating Lin28B can lead to 
cellular transformation. Lin28B is of particular interest in this context because it seems to 
play a role in CSC constitution and maintenance by affecting miRNA maturation in breast 
cancer. (Yang, 2010) Co-expressing EWS-FLI1 and Lin28B was not able to transform primary 
hpMSCs toward Ewing’s sarcoma cells with malignant properties. However, when we 
expressed Lin28B at high levels in MSCs we observed growth in soft agar, confirming the 
transforming capacities of Lin28B. Despite absence of growth in soft agar of MSC expressing 
both EWS-FLI1 and Lin28B, most likely because of inadequate expression of Lin28B, the 
observation that Lin28B alone can transform MSC provides a novel and valuable clue as to 
the molecular components required for MSC transformation to ESFT. 
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In future experiments we will determine whether we can transform MSCs toward Ewing’s 
sarcoma cells by modulating the expression level of other members of the miRNA processing 
machinery such as Dicer, DGCR8 or TARBP2. We will also determine whether the global ESFT 
miRNA expression profile can be reproduced by affecting a specific processing step. Finally, 
we will evaluate whether we can block ESFT growth in mice by exogenous administration of 
specific miRNAs or by pharmacologically targeting components of the processing machinery.  
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4 Material and methods 
Cell culture 
hpMSCs were obtained from femoral head bone marrow of two pediatric patients 
undergoing limb axis correction surgery. MSCs were cultured at low confluence in IMDM, 
10% FCS, and 10ng/ml PDGF-BB (PeProtechEC), and were previously tested for multilineage 
differentiation into adipocytes, chondrocytes, and osteoblasts. 
 
Cloning and RT-PCR 
Lin28B cDNA was amplified from primary ESFT RNA using SuperScript one-step RT-PCR with 
the platinum Taq kit (Invitrogen). The amplified fragment was digested with BamHI and PmeI 
and inserted into a pMSCV Puro retroviral vector (BD Biosciences Clontech). Primer 
sequences for Lin28B were Fwd 5’-
CGGGATCCCGGCCACCATGGCCGAAGGCGGGGCTAGCAAAG-3’ and Rev 5’-
GGGTTTAAACCCTTATGTCTTTTTCCTTTTTTGAACTGAAGGCCCCTTTT-3’. Lin28B and EWS-FLI1 
amplified fragments were digested with respectively MluI/PmeI and BglII/HpaI and inserted 
into a pMSCV-IRES2 retroviral vector (BD Biosciences Clontech). The primer sequences for 
Lin28B were Fwd 5’-CGACGCGTCGGCCACCATGGCCGAAGGCGGGGCTAGCAAAG-3’ and Rev-
5’-GGGTTTAAACCCTTATGTCTTTTTCCTTTTTTGAACTGAAGGCCCCTTTT-3’. 
 
Retroviral infection 
Expression of Lin28B and EWS-FLI1+Lin28B in hpMSCs was achived using Retroviral Gene 
Transfer and Expression (BD Biosciences Clontech), according to the manufacturer’s 
recommendations. Expression of the fusion genes and corresponding proteins were tested in 
all of the batches of cells by RT-PCR and Western blot analysis, respectively, using the mouse 
anti-V5 antibody (Invitrogen) for EWS-FLI1 and the Lin28B antibody (CellSignaling). Infected 
cells were selected with 0.75 µg/mL puromycin for 5 days, and the bulk of the resistant cells 
was used in subsequent experiments.  
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Western blot 
Cell lysis, SDS-PAGE and blotting were performed by standard procedures, and protein bands 
were detected using a chemoluminescent substrate kit (Pierce) according to the 
manufacturer’s recommendations. Primary mouse anti-V5 epitope (Invitrogen), mouse 
antiβ-actin (Sigma), Lin28B (CellSignaling) and IMP-1 (CellSignaling). Secondary antibodies 
were HRP-conjugated goat anti-mouse (Bio-Rad) and goat anti-rabbit immunoglobulin 
(Dako).  
 
Reprogramming protocol 
hpMSCs were cultured in standard FCS-containing medium and infected following the 
standard retroviral protocol. Forty-eight hours after the retroviral infection, hpMSCs were 
washed and incubated in KO medium composed of 20% KO Serum Replacement (Invitrogen, 
GIBCO), 10ng/mL PDGF-BB, 1% penicillin-streptomycin, and 10ng/mL human recombinant 
leukemia inhibitory factor (LIF) (Millipore; Chemicon).  
 
Real-time quantitative RT-PCR 
Total RNA was isolated using Trifast (Peqlab) according to the manufacturer’s 
recommendations. cDNA was obtained using M-MLV reverse transcriptase and RNase H 
minus (Promega). Typically, 500ng of template total RNA and 250ng of random hexamers 
were used per reaction. Real-time PCR amplification was performed using a TaqMan 
Universal PCR mastermix or Power SYBR mix and specific PCR primers in an ABI Prism 7900 
instrument (Applied Biosystems). Relative quantification of each target, normalized to an 
endogenous control Cyclophyllin A, was performed using a comparative Ct method (Applied 
Biosystems). Probes used included k-RAS. SYBR Green primer sequences for the 
quantification of Lin28B, EWS-FLI1, HMGA2 and IMP-1 … transcripts were as follows Lin28B 
Fwd : 5’-GGATTTGGATTCATCTCCATGATAA-3’, Lin28B Rev : 5’-
GAATTCCACTGGTTCTCCTTCTTTT-3’, EWS-FLI1 Fwd : 5’-GTCAACCTCAATCTAGCACAGGG-3’, 
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EWS-FLI1 Rev : 5’-CTGTCGGAGAGCAGCTCCAG-3’, HMGA2 Fwd : 5’-
GCGCCTCAGAAGAGAGGAC-3’, HMGA2 Rev: GTCTTCCCCTGGGTCTCTTAG-3’, IMP-1 Fwd 5’-
GGCCTGAGAATGAGTG-3’, IMP-1 Rev 5’-GAGGGGCAGACAGTGTTG-3’. For microRNA 
quantification, 30ng of total RNA were amplified using miRCURY LNA Universal RT microRNA 
PCR kit (Exiqon, DK) according to the manufacturer’s recommendations. LNA PCR primers 
from Exiquon were used for RT-PCR amplification and snord49a was used as endogenous 
control.  
 
Soft agar colony formation assay 
For the base agar 1% agar was melted in microwave and cooled to 40°C in a water bath. 2X 
KO medium was warmed to 40°C. The two solutions were mixed to give 0.5% agar + 1x KO 
medium. 1.5 ml was poured into 35mm Petri dishes. Cells were trypsinized, counted (5000 
cells/well) and plated on the base agar. For the top agar 0.7% agar was melted and 2X KO 
medium was warmed to 40°C. 3ml of 2X KO medium was mixed to 3ml 0.7% agar. 1ml of the 
top agar mix was added to each plate. 2ml medium was added as top layer and then, 
medium was changed twice a week. Plates were stained with 0.5 ml of 0.005% Crystal Violet 
for > 1 hour, colonies were counted using a dissecting microscope. The plates were 
incubated at 37°C for 5 weeks. 
N.B this experiment was performed by Aurélie Formey.  
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